Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Psychiatric Disease Pipeline: A Strategic Review

Published by: Decision Resources

Published: Jul. 22, 2009 - 27 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

The Psychiatric Disease Pipeline by the Numbers

Companies Developing Psychiatric Disease Agents

GlaxoSmithKline

AstraZeneca

Opportunities and Challenges in the Psychiatric Disease Market

Important Market Opportunities for Psychiatric Diseases

High Unmet Need for Treatment-Resistant and Bipolar Depression
Cognitive Impairment Associated with Schizophrenia

Challenges Facing Companies with Emerging Psychiatric Agents
Increased Treatment by PCPs Challenges Emerging Therapy Uptake
Reimbursement Issues Loom Large for Existing and New Agents Alike

Outlook: Strategies for Developers in a Challenging Sector

Current Market Statistics

Strategies for Emerging Agents

Tables

1. Psychiatric Disease Descriptions

2. Drug Classes Commonly Prescribed to Treat Psychiatric Disease

3. Unmet Needs in Psychiatric Disease

4. GlaxoSmithKline’s Psychiatric Pipeline

5. AstraZeneca’s Psychiatric Pipeline

6. Agents in Development for the Treatment of Cognitive Impairment Associated

with Schizophrenia

7. Top-Selling Psychiatric Drugs, 2008

Figures

1. The Psychiatric Pipeline, NMEs vs. Reformulations

2. The Psychiatric Pipeline, by Target

3. The Psychiatric Pipeline, by Disease

4. The Psychiatric Pipeline, by Phase of Development

5. Leading Psychiatric Pipelines, by Company

6. Psychiatric Pipeline Development Activity, by Company Size

7. GlaxoSmithKline’s Psychiatric Drug Sales, 2003-2008

8; Market Share of Psychiatric Drug Classes, 2008

9. Psychiatric Market Growth, 2003-2008

Abstract

Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in recent years, sustained franchise sales, tolerance for use of multiple drugs within a drug class, and a clinical pipeline of more than 150 agents. Given the heterogeneity of the patient populations in the psychiatric disease sector, unmet need and commercial opportunity are high. We explore ways in which companies are using strategic differentiation and novel targets to overcome challenges and tap sales potential.

Scope
  • 2008 market: 2008 sales; leading drug classes; market-leading companies; commercial
    • position of leading agents.
  • Psychiatric disease pipeline: number of agents in development; disease focus; active
    • companies; profi les of GSK and AZ; mechanisms of action; company type; phase analysis; novel formulations versus reformulations.
  • Psychiatric diseases focused on in this report: schizophrenia; depression; anxiety;
    • addiction; attention-defi cit/hyperactivity disorder (ADHD); cognitive impairment associated with schizophrenia (CIAS).
  • Opportunities in psychiatric diseases: unmet needs of current treatments; treatmentresistant
    • depression; bipolar depression; CIAS; line extensions.
  • Challenges in psychiatric diseases


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009